Late relapse of non‑seminomatous testicular cancer during treatment of multiple sclerosis with interferon β‑1a: A case report

Blancas,Isabel; Cárdenas,Nuria; Delgado,Mayte; Jurado,Jose  Miguel; Legeren,Marta; Villaescusa,Ana; Galvez,Fernando; Yelamos,Marisol

doi:10.3892/ol.2014.2519

Late relapse of non‑seminomatous testicular cancer during treatment of multiple sclerosis with interferon β‑1a: A case report

Authors:
- Isabel Blancas
- Nuria Cárdenas
- Mayte Delgado
- Jose Miguel Jurado
- Marta Legeren
- Ana Villaescusa
- Fernando Galvez
- Marisol Yelamos
View Affiliations

Affiliations: Oncology Unit, Hospital Clinico San Cecilio, Granada 18012, Spain
Published online on: September 10, 2014 https://doi.org/10.3892/ol.2014.2519
Pages: 2179-2182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes. The present study reports a patient diagnosed with non‑seminomatous testicular cancer, stage IB, with a good risk prediction according to the International Germ Cell Cancer Collaborative Group classification. The patient received chemotherapy with bleomycin, etoposide and cisplatin, and achieved complete remission. Eleven years later, while receiving treatment with interferon β‑1a for multiple sclerosis, the patient developed a relapse of the original cancer in the lungs and lymph nodes. The majority of GCTs relapse within the first two years of treatment, while 2‑4% of patients can present with late relapses. There is no clear established association between multiple sclerosis and testicular cancer; we present the hypothesis that the inmunosupressor treatment that was administered for the multiple sclerosis promoted the cancer relapse.

View Figures

View References

1	Motzer RJ, Agarwal N, Beard C, et al: NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 10:672–693. 2009.
2	Lebrun C, Debouverie M, Vermersch P, et al: Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 14:399–405. 2008.
3	Habek M, Brinar VV and Hajnsek S: The association of multiple sclerosis and Hodgkin’s disease: the role of Epstein-Barr virus infection. Mult Scler. 14:284–287. 2008.
4	Ehrlich Y and Baniel J: Late relapse of testis cancer. Urol Clin North Am. 34:253–258. 2007.
5	International Germ Cell Cancer Collaborative Group (IGCCCG). a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 15:594–603. 1997.
6	Frohman EM, Racke MK and Raine CS: Multiple sclerosis - the plaque and its pahogenesis. N Engl J Med. 354:942–955. 2006.
7	Levin MC, Lee S, Gardner LA, et al: Autoantibodies to non-myelin antigens as cotributors to the pathogenesis of multiple sclerosis. J Clin Cell Immunol. 2013:42013.
8	Bellavista E, Santoro A, Galimberti D, et al: Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. Autoimmune Dis. 2014:7397052014.
9	CAMMS223 Trial Investigators. Coles AJ, Compston DA, et al: Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. N Engl J Med. 359:1786–1801. 2008.
10	Mullen JT, Vartanian TK and Atkins MB: Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 358:647–648. 2008.
11	Saxman S, Finch D, Gonin R, et al: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumores: the Indiana University Experience. J Clin Oncol. 16:702–706. 1998.
12	Baniel J, Foster R, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol. 13:1170–1176. 1995.
13	Oldenburg J, Martin JM and Fosså S: Late relapses of germ cell malingnacies: incidence, management, and prognosis. J Clin Oncol. 24:5503–5511. 2006.
14	Sonpavde G, Huston TE and Roth BJ: Management of recurrent testicular germ cell tumors. Oncologist. 12:51–61. 2007.
15	Feldman D, Bosl G, Sheinfeld J and Motzer RJ: Medical treatment of advanced testicular cancer. JAMA. 299:672–684. 2008.
16	Ehrlich Y, Rosenbaum E and Baniel J: Late relapse of testis cancer. Curr Urol Rep. 14:518–524. 2013.
17	Leibovitch I, Baniel J, Rowland RG, et al: Malignant testicular neoplasms in inmunosuppressed patients. J Urol. 155:1938–1942. 1996.
18	Farmakis D, Pectasides M and Pectasides D: Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. Eur Urol. 48:400–407. 2005.
19	Germá-Lluch JR, García del Muro X, Tabernero JM, et al: BOMP/EPI intesive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol. 10:289–293. 1999.
20	De Giorgi U, Rosti G, Aieta M, et al: Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol. 50:1032–1039. 2006.
21	Schmoll HJ, Kollmannsberger C, Metzner B, et al: Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 21:4083–4091. 2003.
22	Ayash LJ, Clarke M, Silver SM, et al: Double dose-intensive chemotherapy with autologus stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant. 27:939–947. 2001.
23	Miki T, Mizutani Y, Akaza H, et al: Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor. Int J Urol. 14:54–59. 2007.
24	Geldart TR, Gale J, Mckendrick J, et al: Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int. 98:353–358. 2006.